Sanofi
Form 6-K
February 07, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2019**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant s name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In February 2019, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1, 99.2, 99.3, 99.4 and 99.5 which are incorporated herein by reference.

**Exhibit List**

| Exhibit No. | Description |
|---|---|
| Exhibit 99.1 | Press release dated February 7, 2019: Sanofi delivers 2018 business EPS growth of 5.1% at CER |
| Exhibit 99.2 | Press release dated February 6, 2019: Sanofi s Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director |
| Exhibit 99.3 | Press release dated February 6, 2019: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) |
| Exhibit 99.4 | Press release dated February 5, 2019: Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma |
| Exhibit 99.5 | Sanofi s Product Sales Statement, for the Product Sales Measuring Period Ended December 31, 2018 |

**Exhibit Index**

| Exhibit No. | Description |
|---|---|
| Exhibit 99.1 | Press release dated February 7, 2019: Sanofi delivers 2018 business EPS growth of 5.1% at CER |
| Exhibit 99.2 | Press release dated February 6, 2019: Sanofi s Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director |
| Exhibit 99.3 | Press release dated February 6, 2019: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) |
| Exhibit 99.4 | Press release dated February 5, 2019: Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma |
| Exhibit 99.5 | Sanofi s Product Sales Statement, for the Product Sales Measuring Period Ended December 31, 2018 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 7, 2019

SANOFI

By /s/ Alexandra Roger
Name: Alexandra Roger
Title: Head of Securities Law and Capital Markets